TWice overnIght High-dose ranoLazIne Pretreatment for preventinG Myocardial iscHemic Damage in Patients With Stable Angina Undergoing percuTaneous Coronary Intervention

Trial Profile

TWice overnIght High-dose ranoLazIne Pretreatment for preventinG Myocardial iscHemic Damage in Patients With Stable Angina Undergoing percuTaneous Coronary Intervention

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Mar 2013

At a glance

  • Drugs Ranolazine (Primary)
  • Indications Myocardial infarction; Myocardial reperfusion injury
  • Focus Therapeutic Use
  • Acronyms TWILIGHT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Mar 2013 Planned End Date changed from 1 Dec 2013 to 1 Dec 2017 as reported by ClinicalTrials.gov.
    • 06 Mar 2013 Planned initiation date changed from 1 Sep 2012 to 1 Jan 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top